Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study-Reference-Cited by-同舟云学术

Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study

Published:2023-12 Issue:12 Volume:22 Page:1150-1159
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Fonseca Elianet,Cabrera-Maqueda Jose M,Ruiz-García Raquel,Naranjo Laura,Diaz-Pedroche Carmen,Velasco Roser,Macias-Gómez Adrià,Milisenda Jose C,Muñoz-Farjas Elena,Pascual-Goñi Elba,Gállego Perez-Larraya Jaime,Saiz Albert,Dalmau Josep,Blanco Yolanda,Graus Francesc,Martinez-Hernandez Eugenia,Aldecoa Iban,Barcelo Maria Ines,Canneti Beatrice,Cedres Susana,Chavarria Alba,Fabregat-Franco Carles,Ferrer-Civeira Maria,Frutos-Alegria Maria Teresa,Guasp Mar,Landete Lamberto,Llufriu Sara,Marti Maria Teresa,Martinez-Rodriguez Jose Enrique,Matas-Garcia Ana,Moreno-Pulido Silvia,Pelayo-Negro Ana Lara,Reig Maria,Riancho Javier,Sánchez-Vizcaíno Cristina,Sanduzzi-Zamparelli Marco,Sepulveda Maria,Silvarrey-Rodriguez Saul,Tagliani Paula

Funder

Caixabank SA

Carlos III Health Institute

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference32 articles.

1. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy;Rotte;Ann Oncol,2018

2. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics;Twomey;AAPS J,2021

3. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study;Johnson;J Immunother Cancer,2019

4. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature;Cuzzubbo;Eur J Cancer,2017

5. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature;Reynolds;Oncologist,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes;The Lancet Neurology;2024-01

2. Immune-checkpoint inhibitors and neurological adverse events;The Lancet Neurology;2023-12